Novo Nordisk A/S
NOVO-B
Κατάταξη σε μετοχές
#107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Τιμή μετοχής
$39.74
Κεφαλαιοποίηση
$175.38B
Αλλαγή (1 ημέρα)
1.28%
Αλλαγή (1 έτος)
-25.58%
Χώρα
DK
Εμπόριο Novo Nordisk A/S (NOVO-B)
Κατηγορία
Healthcare
Δείκτης P/B για Novo Nordisk A/S (NOVO-B)
Δείκτης P/B στις October 2026 TTM: 5.30
Σύμφωνα με τις τελευταίες οικονομικές αναφορές και την τιμή μετοχής της Novo Nordisk A/S, ο τρέχων δείκτης P/B (TTM) είναι 5.30. Στο τέλος του 2024, η εταιρεία είχε P/B δείκτη 19.38.
Ιστορικό P/B για την Novo Nordisk A/S από 2001 έως 2026
Δείκτης P/B στο τέλος κάθε έτους
| Έτος | Δείκτης P/B | Αλλαγή |
|---|---|---|
| 2026 (TTM) | 5.30 | -28.89% |
| 2025 | 7.45 | -61.56% |
| 2024 | 19.38 | -34.02% |
| 2023 | 29.37 | 15.39% |
| 2022 | 25.45 | 6.65% |
| 2021 | 23.87 | 51.77% |
| 2020 | 15.72 | -1.35% |
| 2019 | 15.94 | 12.22% |
| 2018 | 14.20 | -14.34% |
| 2017 | 16.58 | 16.48% |
| 2016 | 14.23 | -34.97% |
| 2015 | 21.89 | 29.23% |
| 2014 | 16.94 | 35.36% |
| 2013 | 12.51 | -0.67% |
| 2012 | 12.60 | 26.42% |
| 2011 | 9.97 | 0.88% |
| 2010 | 9.88 | 77.44% |
| 2009 | 5.57 | 9.91% |
| 2008 | 5.07 | -20.41% |
| 2007 | 6.36 | 25.26% |
| 2006 | 5.08 | 20.40% |
| 2005 | 4.22 | 11.39% |
| 2004 | 3.79 | 16.59% |
| 2003 | 3.25 | 4.96% |
| 2002 | 3.10 | -47.14% |
| 2001 | 5.86 | 0.00% |
Δείκτης P/B για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Δείκτης P/B | Διαφορά Δείκτη P/B | Χώρα |
|---|---|---|---|
| 34.4295 | 549.86% |
US
|
|
| 7.8748 | 48.64% |
US
|
|
| -84.9599 | -1,703.62% |
US
|
|
| 9.0001 | 69.88% |
US
|
|
| 9.7057 | 83.20% |
CH
|
